HCV Drug Resistance Typing EQA/PT Scheme

The aim of the HCVDR EQA is to assess the performance of laboratories in the detection of drug resistance mutations in the hepatitis C virus (HCV) genotypes 1 and 3 (NS3 and NS5 regions) using sequencing techniques.

Total Number of Challenges: 1
Number of Panel Members: 4
Distribution / Testing Period: Q3
Sample NA Target Source Cultured and/or Clinical material
Matrix Panel Format Plasma
Panel Member Target Range Various mutations – NS3 and NS5a regions
Panel Member Sample Volume 1.0 ml
Panel Sample Pre-treatment Requirement Ready for analysis. Treat as clinical samples and analyse accordingly.
Panel Analysis Type Sequence Analysis
Panel Testing Evaluated by various molecular methodologies
Storage / Shipment Conditions <-20°C / Frozen on Dry-ice
Accreditation / Regulatory Status Accredited to ISO 17043
SKU: QAV134167_1 Categories: , , , , Tags: ,

$1,426.53